ESTEVE acquires Prialt and Quzyttir from TerSera Therapeutics. Discover what this deal signals for non-opioid pain drugs and hospital specialty medicines.
TETON-2 phase 3 data show nebulized treprostinil slows IPF lung decline and cuts clinical worsening risk. Analysis of what the NEJM results mean.
C2N Diagnostics brings its PrecivityAD2 blood test to South Korea through BeauBrain Healthcare. Discover what this means for Alzheimer’s diagnosis.
Insulet’s EVOLUTION 2 study shows 68% TIR with no boluses in type 2 diabetes. Analysis of what the FCL data means before the EVOLVE pivotal trial.
Pretzel Therapeutics advances PX578 for POLG disease. Discover how mitochondrial DNA restoration could reshape treatment for rare mitochondrial disorders.
TIXiMED reports preclinical data showing oral TIX100 may prevent weight regain after GLP-1 therapy. Discover what this could mean for obesity treatment.
KARL STORZ wins FDA clearance for the FIVE S 6.5 bronchoscope. Discover what this means for ICU airway management and disposable bronchoscopy trends.
QIAGEN wins FDA clearance for GI panels on QIAstat-Dx Rise. Discover what this means for syndromic testing platforms and molecular diagnostics adoption.
Medtronic plans to acquire Scientia Vascular for $550M. Explore what the deal changes for stroke intervention devices and neurovascular procedure access.
Prothena earns a $50M milestone as Novo Nordisk advances coramitug in Phase 3 for ATTR cardiomyopathy. Discover what this means for amyloid therapies.